Navigation Links
Oncolytics Biotech Inc. Collaborators to Present Combination REOLYSIN(R) and Docetaxel Results at iSBTc Annual Meeting
Date:10/23/2008

CALGARY, Oct. 23 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that an abstract entitled "A Phase I Study to Evaluate Systemic Wild-Type Reovirus (REOLYSIN(R)) in Combination with Docetaxel in Patients with Advanced Malignancies" will be available in the November/December issue of the Journal of Immunotherapy, the official journal of the International Society for Biological Therapy of Cancer (iSBTc). The principal investigator for the trial is Professor Hardev Pandha of the Royal Surrey County Hospital, U.K.

The abstract covers results of the trial (REO 010) up to July 2008. Of the 12 patients treated at the time, three had completed six cycles, one further patient was still on treatment at cycle 7 and four others were ongoing between cycle 1 and cycle 4. Five patients remained on study. The researchers observed one complete resolution of the target lesion in a breast cancer patient with stable disease (SD) of non-target lesions; one partial response in gastric cancer; two SD in lung cancer; and, one SD in melanoma. The researchers concluded that REOLYSIN(R) can be safely combined with docetaxel, that there was objective radiological evidence of anticancer activity and that Phase II studies with this combination are justified. Any significant toxicities observed were consistent with those expected with docetaxel alone.

A poster presentation which will include current results of the trial is scheduled to be presented by Prof. Pandha on November 1, 2008 at the iSBTc annual meeting. The meeting is being held in San Diego, California from October 31-November 2, 2008.

Prof. Pandha is also scheduled to make a poster presentation on November 1, 2008 at the iSBTc meeting entitled "Synergistic Anti-Tumour Activity of Oncolytic Reovirus and Docetaxel in a PC-3 Prostate Cancer Mouse Model." This preclinical research, which demonstrated that combining reovirus and docetaxel treatment resulted in markedly re
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech Inc. Collaborators Present Reovirus and Melanoma Research at EORTC-NCI-AACR Symposium
2. Oncolytics Biotech Inc. Collaborators to Present Preclinical Combination REOLYSIN(R) and Cisplatin Research at EORTC-NCI-AACR Annual Meeting
3. Media Advisory - Oncolytics Biotech Inc. to Present at BIO Investor Forum 2008
4. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
5. Oncolytics Biotech Inc. Completes Initial Scale Up of Manufacturing Process for REOLYSIN(R) to Commercial Scale
6. Media Advisory - Oncolytics Biotech Inc. to Present at Maxim Group Growth Conference
7. Oncolytics Biotech Inc. Announces Issuance of 28th U.S. Patent
8. Oncolytics Biotech Inc. Collaborators to Present REOLYSIN(R) Clinical Trial
9. Oncolytics Biotech Inc. Starts Patient Enrolment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
10. /R E P E A T -- Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours/
11. Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/5/2009)...ire-FirstCall/ -- WaferGen Biosystems, Inc. (OTC B...-of-the-art genetic analysis systems, today announ...ompany,s Scientific Advisory Board. His career ha...vel molecular diagnostics for cancer detection and...putational biology systems for several biotechnolo...
(Date:11/5/2009)...y and vision correction experts listed in the Trus...d at the recently concluded American Academy of Op...isco, California. Dr. Stephen Brint, MD, Dr. Frede...r. Peter Rapoza, MD, Dr. Michael Raizman, MD, Dr. ...dward Manche, MD, and Dr. Parag Majmudar, MD, all ...
(Date:11/4/2009)...wire/ -- DIATHERIX Laboratories, Inc. (DIATHERIX) ...chigan Security Network Homeland Security Market L...maud, Chairman and Chief Executive Officer of DIAT...ced molecular diagnostic testing on bio-preparedne...s and military efforts. ,, "This conference is...
(Date:11/4/2009)...wswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: ...he third quarter ended September 30, 2009. ,, ...improved to $31.0 million or $0.33 per share, as c...r share in the third quarter of 2008. ,, Nek...g efficiencies as compared to a year ago. Total o...
Breaking Biology Technology:WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board 2WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board 3WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board 4Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 2Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 3Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 4Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 5Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 6Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 7Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 8Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 9DIATHERIX Laboratories Presents at Homeland Security Conference 2Nektar Therapeutics Reports Third Quarter 2009 Financial Results 2Nektar Therapeutics Reports Third Quarter 2009 Financial Results 3Nektar Therapeutics Reports Third Quarter 2009 Financial Results 4Nektar Therapeutics Reports Third Quarter 2009 Financial Results 5Nektar Therapeutics Reports Third Quarter 2009 Financial Results 6Nektar Therapeutics Reports Third Quarter 2009 Financial Results 7Nektar Therapeutics Reports Third Quarter 2009 Financial Results 8Nektar Therapeutics Reports Third Quarter 2009 Financial Results 9Nektar Therapeutics Reports Third Quarter 2009 Financial Results 10
...n. 24 Cardica, Inc.,(Nasdaq: CRDC ) today report...s fiscal 2008 second quarter and six months ended ...t commercial progress, with over 1,000,C-Port syst..., an expanding,product line designed to enable min...vancement for our development-stage products," sai...
...argest Chemically Defined Structure Synthesized,in...p Process to Create Synthetic,Organism, ROCKVILLE... Craig Venter Institute (JCVI) has created the lar...sembling the 582,970 base pair,genome of a bacteri...lished,online today in the journal Science by Dan ...
...ers to Treat More Patients, SUNNYVALE, Calif., Ja...obal leader in the field of radiosurgery,announced...tment planning,service to new and existing CyberKn...e centers to access a dedicated team of remote sci...eatment planning, thereby giving,each center the f...
Other Biology Technology:Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress 2Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress 3Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress 4Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress 5Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress 6Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress 7Venter Institute Scientists Create First Synthetic Bacterial Genome 2Venter Institute Scientists Create First Synthetic Bacterial Genome 3Venter Institute Scientists Create First Synthetic Bacterial Genome 4Venter Institute Scientists Create First Synthetic Bacterial Genome 5Venter Institute Scientists Create First Synthetic Bacterial Genome 6Accuray Announces New Treatment Planning Service Offering 2Accuray Announces New Treatment Planning Service Offering 3Accuray Announces New Treatment Planning Service Offering 4
(Date:11/3/2009)...r more than 25 years, all attempts at culturing pe...been unsuccessfuluntil now. For the first time, no...beaded (nucleated) and non-beaded cultured pearls ...ists from Florida Atlantic University,s Harbor Bra... two years of research and experimentation, Drs. H...
(Date:11/3/2009)... and vegetables is a new, patented technology in w...d to label, or "etch" information on produce, ther...abels. The technology has been licensed for use on...sed in New Zealand, Australia, and Pacific Rim cou...frica, Central and South America, Canada, and the ...
(Date:11/3/2009)...hool of Engineering and Applied Science have for t...boratory the enzyme responsible for producing the ... , The research, published Oct. 23 in the jour...opment of other compounds with similarly beneficia...me is one of the most interesting but least unders...
Breaking Biology News(10 mins):Scientists are first to 'unlock' the mystery of creating cultured pearls from the queen conch 2Scientists are first to 'unlock' the mystery of creating cultured pearls from the queen conch 3Laser etching safe alternative for labeling grapefruit 2UCLA researchers reconstitute enzyme that synthesizes cholesterol drug lovastatin 2Retirement Cruise Ship Nearing Launch 50276 1Retirement Cruise Ship Nearing Launch 50276 2Baxa Corporations Dennis Tribble PharmD Now Profiled at Expert411 com for Media and Professional Access 50271 1Baxa Corporations Dennis Tribble PharmD Now Profiled at Expert411 com for Media and Professional Access 50271 2Baxa Corporations Dennis Tribble PharmD Now Profiled at Expert411 com for Media and Professional Access 50271 3BioGlue 28R 29 Surgical Adhesive Hits 500 000 Procedure Milestone Worldwide Company Data Indicates 50267 1BioGlue 28R 29 Surgical Adhesive Hits 500 000 Procedure Milestone Worldwide Company Data Indicates 50267 2BioGlue 28R 29 Surgical Adhesive Hits 500 000 Procedure Milestone Worldwide Company Data Indicates 50267 3BioGlue 28R 29 Surgical Adhesive Hits 500 000 Procedure Milestone Worldwide Company Data Indicates 50267 4
...have flourished ?their beauty evolving over time ?...ssociate professor of genetics at Rutgers and co-a...the whys and wherefores of flowering plants in an ...came on the scene to attract potential pollinators... that accounts for the incredible variety of shape...
...ty" and 3D reconstruction of the volcano on their...chers at Scripps Institution of Oceanography at th...red an active underwater volcano near the Samoan I...the Samoan hot spot, scientists uncovered a submar...r larger underwater volcano, Vailulu,u. Researcher...
...l, the human immunodeficiency virus hijacks that c... itself. New HIV particles roll off the cellular a... and float off to invade other cellular factories....s have now identified an early step in HIV particl...ll, could lead to new drugs that combat HIV infect...
Other Biology News:The evolutionary triumph of flower power 2Researchers discover underwater volcano 2Researchers discover underwater volcano 3Shutting down the HIV assembly line 2
...nd DNA-topoisomersae II inhibitor (IC50 = 59.2 M)....88.55658 Store at: RT CAS: 33419-42-0 S... [5R-[5alpha,5abeta,8aalpha,9beta(R*)]]-9-[(4,6-...etrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-furo[3...
Rabbit Anti-Human ALS2CR2 Polyclonal Antibody, Unconjugated from Proteintech Group, Inc.
Rabbit Anti-IKKbeta / IKK-2 Polyclonal Antibody, Unconjugated from BioVision
...vanced RACE (rapid amplification of cDNA ends) tec...full-length 5' and 3' cDNA ends. The GeneRacer Kit...ptase (RT) for improved amplification of the full-... H portion of SuperScript II RT has been inactivat...
Biology Products: